PTGER3
Prostaglandin E2 receptor EP3 subtype
As of the edition of 20 October 2026, PTGER3 (prostaglandin E2 receptor EP3 subtype, UniProt P43115) has 5 drugs tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43115
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Cancer; Eye; Nutrition and metabolism; Skin and connective tissue; Blood and lymph; Inherited and neonatal
- Registered trials of its drugs
- 294
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Misoprostol | Marketed | Phase 4 | none listed |
| Dinoprostone | Marketed | Phase 4 | none listed |
| Sepetaprost | Marketed | Phase 3 | none listed |
| MVI 200 | Went quiet | Phase 3 | none listed |
| MVI 100 | Went quiet | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Infan Industria Quimica Farmaceutica Nacional | Route B |
| Linepharma | Route B |
The other 3 companies at PTGER3
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at PTGER3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.